Real-World check: does upadacitinib tame ulcerative colitis in china?
NCT ID NCT06838845
First seen Nov 26, 2025 · Last updated Jun 20, 2026 · Updated 22 times
Summary
This study follows 80 Chinese adults with moderate to severe ulcerative colitis who are already prescribed upadacitinib by their doctor. Researchers will collect routine medical data over one year to see if the drug improves symptoms like bloody diarrhea. No extra tests or visits are required beyond standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Sun-Yat Sen University /ID# 272997
RECRUITINGGuangzhou, Guangdong, 510080, China
-
The Second Affiliated Hospital Of Zhengzhou University /ID# 274754
RECRUITINGZhengzhou, Henan, 450014, China
-
The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 274753
RECRUITINGGuangzhou, Guangdong, 510655, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
upadacitinib
What this could lead to
If successful, this study could confirm that upadacitinib is effective for managing ulcerative colitis in Chinese patients, supporting its use in routine care.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only follows 80 people for one year, which is small and short-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.